Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by University of Alberta.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Deepali Kumar, University of Alberta
ClinicalTrials.gov Identifier:
NCT00677482
First received: May 12, 2008
Last updated: April 20, 2012
Last verified: April 2012
  Purpose

Cytomegalovirus (CMV) is the most common viral infection in patients who have undergone a transplant.Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. The purpose of this study is to assess how the virus interacts with the patient's immune system, so that in the future it may be possible to develop better ways to prevent and treat the virus infection.


Condition
Transplant

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cytomegalovirus (CMV) microRNA Expression in Vivo and Immune Evasion Correlates

Further study details as provided by University of Alberta:

Estimated Enrollment: 30
Study Start Date: April 2008
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Solid organ tranplant recipients with both asymptomatic CMV viremia and symptomatic CMV disease are eligible for inclusion in the study. This include liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.

Criteria

Inclusion Criteria:

Male or female patients who fulfill the following criteria are eligible for inclusion:

  • Age >=18 years
  • Solid Organ Transplant Recipients
  • Documented CMV disease or asymptomatic CMV viremia

Exclusion Criteria:

  • Unable to comply with protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00677482

Locations
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G-2E1
Sponsors and Collaborators
University of Alberta
Investigators
Principal Investigator: Atul Humar, MD University of Alberta
  More Information

Publications:
Responsible Party: Deepali Kumar, Assistant Professor of Medicine, University of Alberta
ClinicalTrials.gov Identifier: NCT00677482     History of Changes
Other Study ID Numbers: 7304
Study First Received: May 12, 2008
Last Updated: April 20, 2012
Health Authority: Canada: Health Canada

Keywords provided by University of Alberta:
liver transplant
lung transplant
kidney transplant
heart transplant
CMV microRNA

ClinicalTrials.gov processed this record on October 23, 2014